LL-37 Benefits: What Studies Report

LL-37 is the 37-amino-acid peptide released from the human cathelicidin precursor protein. It is produced by epithelial cells and by neutrophils, and it appears across immunology, dermatology, dentistry and antimicrobial chemistry literature. Because it is an endogenous molecule with broad laboratory activity, it attracts a wide range of claimed "benefits" online. The published record is narrower than those claims: it is dominated by in-vitro assays and animal models, with very little human interventional data on LL-37 itself as an administered agent.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question. Nothing below describes a protocol, and no outcome is presented as established in people.

How the Evidence Should Be Read

The strength of a finding depends on where it came from. Most of what exists for LL-37 sits in the first two rows of the table below.

Antibacterial Activity: In-Vitro Findings

The largest single domain is direct antibacterial activity. A 2026 report in the European Journal of Medicinal Chemistry described an LL-37-derived peptide and its antimicrobial potential against multidrug-resistant pathogens (PMID 41485275), placing it in the category of medicinal-chemistry work on sequence derivatives rather than on the native peptide as a therapy.

A 2024 paper in Antibiotics examined LL-37-derived synthetic peptides in the context of orthopaedic infections, and researchers measured cytotoxicity alongside antimicrobial properties in the same work (PMID 39200064). That pairing matters: in cathelicidin chemistry, host-cell toxicity and antibacterial potency are typically assessed together rather than separately, because the same membrane-disrupting behaviour can act on both bacterial and mammalian membranes.

Why Derivatives Rather Than LL-37 Itself

Both of the reports above studied derived or synthetic sequences rather than administering native LL-37 (PMID 41485275, PMID 39200064). A separate engineering line of work reported a sonosensitive diphenylalanine-based broad-spectrum antimicrobial peptide in Nature Biomedical Engineering in 2025 (PMID 40316686), illustrating how the antimicrobial-peptide field has moved toward engineered scaffolds and activation strategies. None of this work establishes a systemic human use for LL-37.

Wound and Soft-Tissue Infection: Animal Evidence

A 2021 study in Antibiotics evaluated the efficacy of cathelicidin LL-37 in a mouse model of MRSA wound infection (PMID 34680791). This is one of the clearest examples of LL-37 itself, rather than a derivative, being tested in a living animal against a resistant pathogen in a wound setting. The finding is animal-model evidence for local application in infected wounds, and it does not extend to human wound care, cosmetic skin outcomes, or scar appearance, which that study did not address (PMID 34680791).

Cathelicidins as a Requirement for Other Drugs to Work

A 2020 paper in The Journal of Infectious Diseases reported that the efficacy of antigonococcal CMP-nonulosonate therapeutics required cathelicidins (PMID 32692363). The direction of effect there is indirect and mechanistic: the host's own cathelicidin system was necessary for a separate antimicrobial strategy to function, which is a different proposition from LL-37 being given as a treatment.

Antiviral Research: Binding, Not Clinical Outcomes

A 2025 report in Frontiers in Cellular and Infection Microbiology described the vitamin D-inducible antimicrobial peptide LL-37 binding SARS-CoV-2 Spike and the accessory proteins ORF7a and ORF8 (PMID 41064641). The measured endpoint was molecular interaction. Binding to a viral protein in a laboratory system is a mechanistic observation; the study did not report reduced infection rates, symptom duration or clinical severity in people (PMID 41064641). Claims that LL-37 prevents or shortens respiratory infections in humans are not supported by that work.

Oral and Periodontal Research

Antimicrobial peptide biology features heavily in periodontitis research because the periodontal pocket is a chronic, polymicrobial, inflamed environment. A 2025 study in ACS Nano reported engineered macrophage membrane-camouflaged nanodecoys designed to reshape the infectious microenvironment for periodontitis treatment (PMID 40228155). That work is preclinical delivery-platform research; the relevant takeaway for readers is the direction of the field — local, engineered delivery into an infected niche — rather than any human periodontal outcome (PMID 40228155).

Skin Conditions: Where LL-37 Is Studied as a Problem

One of the most important correctives to a "benefits" framing comes from dermatology. A 2025 review in Frontiers in Immunology surveyed advances in the pathogenesis of rosacea (PMID 41646975), a condition in which cathelicidin peptide activity is examined as part of the inflammatory mechanism rather than as something desirable. In the same disease area, a 2025 paper in the International Journal of Molecular Sciences investigated cannabigerol as a dual-pathway modulator targeting vascular and inflammatory crosstalk in rosacea (PMID 40725084) — that is, researchers were looking for ways to dampen this inflammatory axis, not amplify it.

Readers who encounter LL-37 described as a "skin-rejuvenating" or "anti-inflammatory" peptide should weigh that against the rosacea literature, where the cathelicidin pathway is treated as a target to modulate (PMID 41646975, PMID 40725084).

Atopic Dermatitis and the Vitamin D Angle

Because cathelicidin expression is vitamin D-inducible (PMID 41064641), some of the human evidence people associate with LL-37 is actually vitamin D evidence. A randomised controlled trial published in JEADV in 2024 tested weekly vitamin D supplementation in children and measured the severity of atopic dermatitis together with type 2 immunity biomarkers (PMID 38483248). That trial tested a vitamin, not LL-37, and any inference from it to administered peptide effects is an extrapolation the study did not make (PMID 38483248).

Exercise and Salivary Antimicrobial Peptides

Human data do exist on natural fluctuations. A 2024 study in the American Journal of Physiology — Regulatory, Integrative and Comparative Physiology examined the acute salivary antimicrobial peptide secretion response to different exercise intensities and durations (PMID 39155711). The outcome measured was secretion into saliva after exercise bouts, in humans. This is descriptive physiology: it reported how an endogenous system responded to a stimulus and did not test whether altering that response changed illness rates (PMID 39155711).

Neutrophil Function in Clinical Populations

Cathelicidin biology also appears in haematology, where neutrophil antimicrobial capacity is a clinical endpoint. A 2024 study in Blood Advances assessed neutrophil functions in patients with neutropenia due to glycogen storage disease type 1b who were treated with empagliflozin (PMID 38531056). The intervention studied was empagliflozin, and the measurements concerned host neutrophil function in a rare disease population (PMID 38531056). It is an example of how antimicrobial defence is quantified in people rather than evidence for peptide administration.

Outcome Domains at a Glance

Claims With Weak or Absent Support in the Cited Literature

Several commonly circulated "LL-37 benefits" have no basis in the studies cited on this page. None of the papers above reported effects on fat loss, body composition, athletic performance, cognition, longevity, hormone levels, chronic fatigue, mould illness or Lyme disease. The strongest infection findings located here were an animal wound model (PMID 34680791) and laboratory antimicrobial characterisation (PMID 41485275), and the skin literature cited treats the cathelicidin pathway as a target for suppression in rosacea (PMID 41646975). Where a benefit is claimed but only in-vitro or animal data exist, the honest description is "studied in the laboratory", not "shown to work".

Tolerability and Toxicity: What Studies Report

Cytotoxicity is an explicit endpoint in this field rather than an afterthought: the 2024 Antibiotics paper on LL-37-derived synthetic peptides for orthopaedic infections assessed cytotoxicity together with antimicrobial properties (PMID 39200064). Medicinal-chemistry work on derived sequences is likewise framed around improving antimicrobial potential against resistant organisms, which is the context in which sequence modification is pursued (PMID 41485275). On the biology side, the rosacea pathogenesis literature indicates that heightened activity in this pathway is associated with inflammatory skin disease rather than with benefit (PMID 41646975). No human safety dataset for administered LL-37 is present among the papers cited here.

Regulatory and Practical Context

LL-37 is an endogenous human peptide that appears in the literature as a research material and as a scaffold for drug design (PMID 39200064). Peptide material sold for laboratory work is typically labelled research-use-only and is not a medicine; research-use-only labelling means the material has not been evaluated for human administration. Questions about any specific product, medical condition or medication belong with a licensed clinician.

Bottom Line From the Cited Papers

Across the papers cited on this page, LL-37 emerges as a well-characterised component of innate immunity with reported antibacterial activity in culture and in a mouse wound-infection model (PMID 34680791), demonstrated binding to specific viral proteins in a laboratory setting (PMID 41064641), measurable acute changes in human saliva after exercise (PMID 39155711), and a mechanistic role in inflammatory skin disease that researchers are working to modulate downward (PMID 40725084). That is a research programme, not a list of benefits.

References

• LL-37-derived peptide shows promising antimicrobial potential against multidrug-resistance pathogens (European Journal of Medicinal Chemistry, 2026)
• Antimicrobial Properties and Cytotoxicity of LL-37-Derived Synthetic Peptides to Treat Orthopedic Infections (Antibiotics, 2024)
• Efficacy of Cathelicidin LL-37 in an MRSA Wound Infection Mouse Model (Antibiotics, 2021)
• Vitamin D-inducible antimicrobial peptide LL-37 binds SARS-CoV-2 Spike and accessory proteins ORF7a and ORF8 (Frontiers in Cellular and Infection Microbiology, 2025)
• Efficacy of Antigonococcal CMP-Nonulosonate Therapeutics Require Cathelicidins (The Journal of Infectious Diseases, 2020)
• Engineered Macrophage Membrane-Camouflaged Nanodecoys Reshape the Infectious Microenvironment for Efficient Periodontitis Treatment (ACS Nano, 2025)
• A sonosensitive diphenylalanine-based broad-spectrum antimicrobial peptide (Nature Biomedical Engineering, 2025)
• Advances in the pathogenesis of rosacea (Frontiers in Immunology, 2025)
• Targeting Vascular and Inflammatory Crosstalk: Cannabigerol as a Dual-Pathway Modulator in Rosacea (International Journal of Molecular Sciences, 2025)
• Effect of weekly vitamin D supplementation on the severity of atopic dermatitis and type 2 immunity biomarkers in children: A randomized controlled trial (JEADV, 2024)
• Acute salivary antimicrobial peptide secretion response to different exercise intensities and durations (American Journal of Physiology — Regulatory, Integrative and Comparative Physiology, 2024)
• Neutrophil functions in patients with neutropenia due to glycogen storage disease type 1b treated with empagliflozin (Blood Advances, 2024)